Description of Clinical Expertise

Dr. Kim is an interventional pulmonologist at Penn Medicine. He has completed 8 years of post-graduate training and is triple-board certified in internal medicine, pulmonary disease, and interventional pulmonology. Dr. Kim has clinical expertise in pulmonology and medical critical care, and has received additional advanced training in interventional pulmonology and thoracic oncology. He specializes in treating patients with pulmonary nodules, abnormal chest CT scans, lung cancer, endobronchial disease, airway complications, pleural effusions, and chronic obstructive pulmonary disease, among other pulmonary conditions. Specifically, Dr. Kim has procedural expertise in diagnostic and therapeutic bronchoscopy, rigid bronchoscopy, robotic bronchoscopy, advanced navigational bronchoscopic techniques, endobronchial ultrasound-guided transbronchial needle aspiration and biopsy, balloon bronchoplasty, relief of airway stenosis, foreign body removal, endobronchial tumor debulking, airway stent placement, endoscopic airway electrosurgery, chest tube insertion, indwelling tunneled pleural catheter placement, and percutaneous tracheostomy, among other minimally invasive procedures.

Description of Research Expertise

Dr. Kim has received formal training in clinical epidemiology and biostatistics and has specific research expertise in clinical epidemiology, observational study design, clinical trial design, biostatistics, database management, data collection, statistical analysis, and scientific writing. His research aims to optimize the diagnostic process in thoracic oncology, with particular focuses on lung cancer screening and risk stratification of pulmonary nodules.

With the NCI-funded PROSPR-Lung Consortium, Dr. Kim has led multicenter studies evaluating disparities in lung cancer screening follow-up testing, which have identified opportunities to improve health equity in lung cancer screening care. Separately, he is invested in improving current pulmonary nodule risk stratification practices. Recent developments in technology have led to the development of a bevy of novel biomarkers designed to help clinicians risk stratify pulmonary nodules. His research seeks to determine the clinical utility and impact on medical decision-making of novel risk stratification biomarkers. He is the principal investigator for the NCI-funded (K08CA279881) ARCADES pragmatic randomized controlled trial to study the clinical effectiveness of an artificial intelligence radiomics-based biomarker (NCT05968898).